- Home
- NMAI vs LAB Comparison
NMAI vs LAB Comparison
Compare NMAI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMAI
- LAB
- Stock Information
- Founded
- NMAI 2021
- LAB 1999
- Country
- NMAI United States
- LAB United States
- Employees
- NMAI N/A
- LAB N/A
- Industry
- NMAI Investment Managers
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- NMAI Finance
- LAB Industrials
- Exchange
- NMAI Nasdaq
- LAB Nasdaq
- Market Cap
- NMAI 382.1M
- LAB 451.0M
- IPO Year
- NMAI N/A
- LAB 2011
- Fundamental
- Price
- NMAI $12.11
- LAB $1.07
- Analyst Decision
- NMAI
- LAB Buy
- Analyst Count
- NMAI 0
- LAB 2
- Target Price
- NMAI N/A
- LAB $2.50
- AVG Volume (30 Days)
- NMAI 74.8K
- LAB 937.2K
- Earning Date
- NMAI 01-01-0001
- LAB 05-06-2025
- Dividend Yield
- NMAI 13.14%
- LAB N/A
- EPS Growth
- NMAI N/A
- LAB N/A
- EPS
- NMAI 0.64
- LAB N/A
- Revenue
- NMAI N/A
- LAB $169,687,000.00
- Revenue This Year
- NMAI N/A
- LAB N/A
- Revenue Next Year
- NMAI N/A
- LAB $12.77
- P/E Ratio
- NMAI $19.03
- LAB N/A
- Revenue Growth
- NMAI N/A
- LAB 33.86
- 52 Week Low
- NMAI $10.60
- LAB $0.95
- 52 Week High
- NMAI $12.55
- LAB $2.74
- Technical
- Relative Strength Index (RSI)
- NMAI 60.20
- LAB 44.50
- Support Level
- NMAI $11.98
- LAB $0.95
- Resistance Level
- NMAI $12.19
- LAB $1.21
- Average True Range (ATR)
- NMAI 0.14
- LAB 0.10
- MACD
- NMAI 0.06
- LAB -0.01
- Stochastic Oscillator
- NMAI 90.36
- LAB 31.58
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.